| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Wim Ceelen | Q43121460 |
| P2093 | author name string | C Vervaet | |
| J P Remon | |||
| L De Smet | |||
| P2860 | cites work | Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 |
| Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel | Q33183577 | ||
| Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis. | Q33345134 | ||
| 5-FU-hydrogel inhibits colorectal peritoneal carcinomatosis and tumor growth in mice | Q33647418 | ||
| Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer | Q33913953 | ||
| Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer | Q34055165 | ||
| Lymphatic transport of liposome-encapsulated drugs following intraperitoneal administration - effect of lipid composition | Q86835873 | ||
| In situ cross-linkable hyaluronan hydrogels containing polymeric nanoparticles for preventing postsurgical adhesions | Q51018554 | ||
| Intraperitoneal administration of doxorubicin encapsulating liposomes against peritoneal dissemination. | Q52540062 | ||
| Preparation of camptothecin-loaded PCEC microspheres for the treatment of colorectal peritoneal carcinomatosis and tumor growth in mice. | Q53217386 | ||
| Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
| Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture. | Q55482290 | ||
| Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C | Q70369682 | ||
| The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies | Q71415334 | ||
| Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study | Q73368601 | ||
| Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC) | Q73560191 | ||
| Organ distribution of cisplatin after intraperitoneal administration of cisplatin-loaded microspheres | Q74363291 | ||
| The administration of hypotonic intraperitoneal cisplatin during operation as a treatment for the peritoneal dissemination of gastric cancer | Q77579966 | ||
| Administration in a hypotonic solution is preferable to dose escalation in intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in rats | Q77961992 | ||
| Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer | Q79150738 | ||
| Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time | Q79157121 | ||
| Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group | Q80428523 | ||
| Clinical delivery system for intraperitoneal hyperthermic chemotherapy. | Q34268781 | ||
| Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer | Q34590724 | ||
| Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer | Q35187343 | ||
| Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia | Q35721975 | ||
| Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies | Q36375924 | ||
| Principles and practice of intraperitoneal chemotherapy for ovarian cancer | Q36732590 | ||
| Pharmacokinetics and tissue distribution of intraperitoneal 5-fluorouracil with a novel carrier solution in rats | Q37245482 | ||
| Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. | Q37252019 | ||
| Effects of carrier on disposition and antitumor activity of intraperitoneal Paclitaxel | Q37415150 | ||
| Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer | Q37415227 | ||
| Transport of Model Compounds across the Peritoneal Membrane in the Rat | Q39229778 | ||
| An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels. | Q39431099 | ||
| Improving intraperitoneal chemotherapeutic effect and preventing postsurgical adhesions simultaneously with biodegradable micelles | Q39431203 | ||
| Intraoperative versus early postoperative intraperitoneal chemotherapy after cytoreduction for colorectal peritoneal carcinomatosis: an experimental study. | Q39491271 | ||
| Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer | Q39526281 | ||
| The performance of expansile nanoparticles in a murine model of peritoneal carcinomatosis | Q39636663 | ||
| In vivo efficacy of paclitaxel-loaded injectable in situ-forming gel against subcutaneous tumor growth. | Q39726118 | ||
| Hybrid films from blends of chitosan and egg phosphatidylcholine for localized delivery of paclitaxel | Q40416260 | ||
| Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells | Q40678726 | ||
| Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. | Q40698258 | ||
| The effect of volume on the distribution of substances instilled into the peritoneal cavity | Q41354543 | ||
| Peritoneal retention of liposomes: Effects of lipid composition, PEG coating and liposome charge | Q42923797 | ||
| Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. | Q43130795 | ||
| Fluid dynamics in man of an intraperitoneal drug delivery solution: 4% icodextrin | Q43560893 | ||
| Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy | Q43587312 | ||
| Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum | Q43887584 | ||
| 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer | Q43941230 | ||
| Development of a nanocrystalline Paclitaxel formulation for HIPEC treatment. | Q43989079 | ||
| Hypersensitivity reactions from taxol | Q44119231 | ||
| Cisplatin incorporated in microspheres: development and fundamental studies for its clinical application | Q44434546 | ||
| Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions | Q44524632 | ||
| Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles | Q44895301 | ||
| Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. | Q44919656 | ||
| The effects of adjuvant experimental radioimmunotherapy and hyperthermic intraperitoneal chemotherapy on intestinal and abdominal healing after cytoreductive surgery for peritoneal carcinomatosis in the rat. | Q46422975 | ||
| A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study | Q46445766 | ||
| Drug release mechanism of paclitaxel from a chitosan-lipid implant system: effect of swelling, degradation and morphology. | Q47996161 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | drug delivery | Q1392806 |
| antineoplastic | Q2853144 | ||
| intraperitoneal chemotherapy | Q6094956 | ||
| nanocapsule | Q17157402 | ||
| neoplasm | Q1216998 | ||
| delayed-action preparation | Q73225615 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 720858 | |
| P577 | publication date | 2013-03-25 | |
| P1433 | published in | The Scientific World Journal | Q7762585 |
| P1476 | title | Optimization of drug delivery systems for intraperitoneal therapy to extend the residence time of the chemotherapeutic agent. | |
| P478 | volume | 2013 |
| Q34785218 | Chitosan/siRNA nanoparticles targeting cyclooxygenase type 2 attenuate unilateral ureteral obstruction-induced kidney injury in mice. |
| Q36402123 | Drug delivery systems for ovarian cancer treatment: a systematic review and meta-analysis of animal studies. |
| Q52866005 | Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma. |
| Q38741048 | Epirubicin loading in poly(butyl cyanoacrylate) nanoparticles manifests via altered intracellular localization and cellular response in cervical carcinoma (HeLa) cells |
| Q60917106 | Evaluation of the Biological Behavior of a Gold Nanocore-Encapsulated Human Serum Albumin Nanoparticle (Au@HSANP) in a CT-26 Tumor/Ascites Mouse Model after Intravenous/Intraperitoneal Administration |
| Q91781537 | Exploring the Use of Pegylated Liposomal Doxorubicin (Caelyx®) as Pressurized Intraperitoneal Aerosol Chemotherapy |
| Q47165034 | Nanoparticle as a novel tool in hyperthermic intraperitoneal and pressurized intraperitoneal aerosol chemotheprapy to treat patients with peritoneal carcinomatosis. |
| Q39129504 | Nanoparticle drug-delivery systems for peritoneal cancers: a case study of the design, characterization and development of the expansile nanoparticle |
| Q41936079 | Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma |
| Q90127233 | Numerical modeling of high-intensity focused ultrasound-mediated intraperitoneal delivery of thermosensitive liposomal doxorubicin for cancer chemotherapy |
| Q28544821 | Peritoneal tumor carcinomatosis: pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs |
| Q90356540 | Pharmacologic Properties of the Carrier Solutions for Hyperthermic Intraperitoneal Chemotherapy: Comparative Analyses Between Water and Lipid Carrier Solutions in the Rat Model |
| Q92618128 | Photodynamic therapy and photothermal therapy for the treatment of peritoneal metastasis: a systematic review |
| Q90754497 | Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer |
| Q47444293 | Suitability of the AUC Ratio as an Indicator of the Pharmacokinetic Advantage in HIPEC. |
| Q38679465 | Tumour tissue transport after intraperitoneal anticancer drug delivery |
Search more.